Home About News Products Cooperation Tender Join Us Contact Member

 

QQ图片20180309110048.jpg


In October 2000, Beijing Sunho  Modern Pharmaceutical Development Co., Ltd. was established.


In 2003, he obtained a GSP certificate and entered the pharmaceutical sales field.


In June 2005, the wholly-owned subsidiary Guangdong Sunho  Pharmaceutical Co., Ltd. was established.


In August 2007, the Zhongguancun New Third Board was listed. Securities are referred to as Sunho  Pharmaceutical. The stock code is 430017.

 

In September 2011, Guangdong Sunho  Pharmaceutical Co., Ltd. obtained a new version of the GMP certificate, becoming the first company in Guangdong Province who  pass a new GMP certification.

 

In February 2012, Rifamycin sodium for injection, octreotide acetate for injection, octreotide acetate injection, and compound digestive enzymes were identified as high-tech products in Guangdong Province.


In July 2012, Guangdong Sunho  Pharmaceutical Co., Ltd. was identified as a high-tech enterprise.


In October 2012,  Controlled  of  Changchun Tiancheng  Pharmaceutical Co., Ltd.

 

In July 2014, the wholly-owned subsidiary Beijing Sunho  Yingsheng Pharmaceutical Co., Ltd. was established.


In October 2014, rifamycin sodium for injection, octreotide acetate for injection, octreotide acetate injection, and compound digestive enzymes were identified as high-tech products in Guangdong Province.

 

Guangdong Sunho  Pharmaceutical Co., Ltd. invested 500 million to open the second phase of the international project, according to the EU, the United States GMP requirements to build lyophilized powder injection, small volume liquid  injection, oral solid preparation production line.


In May 2015, strategic investment was introduced. Registered capital was changed from RMB 77,277,200 to RMB 8,427,720.


In September 2015, the financial investment was reintroduced. The registered capital was changed from RMB 82.7772 million to 91.972 million yuan.

 

In 2016, the company’s flagship product, “Stars, Magpies,” was listed in the 2016 China Pharmaceutical Brand List.

 

In March 2017, the company obtained the clinical trial approval document for "Osstaphane phosphate orally disintegrating tablets" issued by the State Food and Drug Administration.


In March 2017, it obtained the Beijing Engineering Technology Research Center for Sustained Release Control technology.


In October 2017, it was recognized as a national high-tech enterprise.


In December 2017, it obtained the Beijing Intellectual Property Operation Pilot Enterprise.